Thryve Peptides
CJC-1295 without DAC (5mg) + IPA (5mg) Combo
CJC-1295 without DAC (5mg) + IPA (5mg) Combo
Couldn't load pickup availability
CJC-1295 Without DAC + IPA (10MG TOTAL)
Optimized peptide blend for research on growth hormone modulation and peptide interaction.
- CJC-1295 without DAC is a short-acting analog of growth hormone–releasing hormone (GHRH 1–29), designed for controlled peptide studies.
- Combined with IPA (Ipamorelin), a selective secretagogue studied for complementary action on GH release through distinct receptor pathways.
- Independently verified for composition, purity, and consistency by Vanguard Laboratory.
For laboratory research use only. Not for human consumption.
Scientific Evidence
CJC-1295 without DAC is a modified GHRH analog that maintains biological activity while exhibiting a shorter half-life compared to the DAC-bound form. Research demonstrates acute stimulation of pulsatile GH release in controlled environments (PubMed 16492960).
Ipamorelin (IPA) is a pentapeptide studied for its selectivity at the ghrelin receptor, promoting GH release without affecting cortisol or prolactin levels (PubMed 9288582).
When combined, CJC-1295 without DAC and IPA are often studied for potential synergistic effects on GH pulse frequency and amplitude in peptide research models (PubMed 16507602).
Regulatory Status: CJC-1295 and Ipamorelin are not FDA-approved for human or veterinary use. These peptides are supplied strictly for laboratory research applications.
